Studies related to Cancer Mortality and Vitamin K

The Effect Of Menatetrenone, A Vitamin K2 Analog, On Disease Recurrence And Survival In Patients With Hepatocellular Carcinoma After Curative Treatment: A Pilot Study

Effect Decrease
Trial Design Cohort
Trial Length 6+ Months
Number of Subjects 61
Gender Both Genders
Age Range 45-64, 65+
Body Types Average, Underweight
Notes for this study:
A pilot study noted that recurrence rates in the group given 45mg MK-4 daily were 12.5% at 12 months, 39.0% at 24 months, and 64.3% at 36 months which significantly outperformed control. The survival rates showed a very strong trend to be improved, but failed to reach statistical significance.

Effect Of Menatetrenone, A Vitamin K2 Analog, On Recurrence Of Hepatocellular Carcinoma After Surgical Resection: A Prospective Randomized Controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 101
Gender Both Genders
Age Range 45-64, 65+
Body Types Average, Underweight
Notes for this study:
Supplementation of pharmacological doses of MK-4 (45mg) daily was able to improve the survival rates to 78.3%, 58.1%, and 31.0% (12, 36, and 60 months) whereas in control all persons passed away at month 36. The recurrence rates showed a strong trend towards reduction (0.545) but failed to reach significance.